IPF Testimony: Jim Hatfield Continues his Wife’s Legacy

IPF Testimony: Jim Hatfield Continues his Wife’s Legacy

https://www.youtube.com/watch?v=JcZuUt8jXBI The average survival of patients with idiopathic pulmonary fibrosis (IPF) is between three and five years after diagnosis, and only 20% of them survive past this time. Like many others, Anita Hatfield struggled for three years with the disease and died last March from complications related to idiopathic pulmonary fibrosis.

Efficacy and Safety of Nintedanib (Ofev), an IPF Drug, Confirmed in New Analyses of Phase 3 Trials

New analyses, presented at the American Thoracic Society (ATS) 2016 Annual Conference, further support the efficacy and safety of nintedanib (Ofev) in treating idiopathic pulmonary fibrosis (IPF). Boehringer Ingelheim shared a host of data at the meeting, establishing nintedanib as an important player in IPF management, irrespective of disease severity. “IPF…

Getting Help with Pulmonary Rehabilitation: Margaret’s Story

https://www.youtube.com/watch?v=QZjVxgHXR8E I Am News, a local community news project from Swansea, UK, shared this video where you can meet Margaret Barnard. Margaret is a chronic obstructive pulmonary disease patient, a member of the British Lung Foundation and Breathe Easy Group. In this video, she shares a little bit…

What are Stem Cells and How Can They Be Used?

You’ve probably already heard about stem cells and their healing power. Several disease can be treated by using stem cells treatments and therapies, pulmonary fibrosis being one of them. But what exactly are stem cells and how can they be so versatile to be able to be used as…

A Patient’s Life with IPF: A Fresh Start

In this recent line of videos by this father of two named Mark, we are presented with his story of resilience and strength. In 2014, his health was rapidly declining and he found himself bedridden for most of the year because of the deterioration in his lung functions due to…